Gilead Sciences agreed to buy Forty Seven for about US$4.9 billion to advance into one of the hottest areas of pharmaceutical research, cancer treatments that harness the immune system to fight tumors, reported Bloomberg.
In a statement on Monday, Gilead said it would pay US$95.50 a share for Forty Seven, a 96% premium to the group’s closing share price on Thursday, February 27, when talks between the two companies leaked. Shares in Forty Seven, which was founded in 2015 and is based in Menlo Park, California, surged 61% following the announcement of the deal.
“This agreement builds on Gilead’s presence in immuno-oncology and adds significant potential to our clinical pipeline,” said Daniel O’Day, Gilead’s chief executive. “With a profile that lends itself to combination therapies, magrolimab could potentially have transformative benefits for a range of tumour types.”
Gilead is not alone in turning to M&A to bolster its portfolio of cancer drugs. Early last year Bristol-Myers Squibb purchased Celgene for US$93 billion, while Pfizer snapped up Array BioPharma for US$11 billion in June. Rivals Eli Lilly and GlaxoSmithKline have also bet billions of dollars on cancer treatments over the past 18 months.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Clifford Chance Expands Global Antitrust Team with New Partner
Dec 6, 2024 by
CPI
Spain’s Financial Regulator Awaits Antitrust Decision on BBVA’s Hostile Bid for Sabadell
Dec 5, 2024 by
CPI
RealPage Seeks Dismissal of DOJ Antitrust Suit, Citing Legal Flaws
Dec 5, 2024 by
CPI
EU Competition Chief Signals Potential Google Breakup Amid Big Tech Scrutiny
Dec 5, 2024 by
CPI
Turkey Closes Antitrust Probe into Meta’s Threads-Instagram Practices
Dec 5, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Moats & Entrenchment
Nov 29, 2024 by
CPI
Assessing the Potential for Antitrust Moats and Trenches in the Generative AI Industry
Nov 29, 2024 by
Allison Holt, Sushrut Jain & Ashley Zhou
How SEP Hold-up Can Lead to Entrenchment
Nov 29, 2024 by
Jay Jurata, Elena Kamenir & Christie Boyden
The Role of Moats in Unlocking Economic Growth
Nov 29, 2024 by
CPI
Overcoming Moats and Entrenchment: Disruptive Innovation in Generative AI May Be More Successful than Regulation
Nov 29, 2024 by
Simon Chisholm & Charlie Whitehead